What BioAge Labs, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 2 | 13 |
| Total trades | 10 | 36 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 59,934 | 219,117 |
| Disposed | 62,566 | 440,689 |
| Net activity | −2,632 | −221,572 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Barton Shane | Principal Accounting Officer | Jun 30 | Open-market sale · S | −20,216 | $25.19 | −$509K | 0 |
| Barton Shane | Principal Accounting Officer | Jun 30 | Exercise / conversion · M | +7,861 | $4.38 | +$34.4K | 20,216 |
| Barton Shane | Principal Accounting Officer | Jun 30 | Exercise / conversion · M | +4,065 | $4.30 | +$17.5K | 12,355 |
| Barton Shane | Principal Accounting Officer | Jun 30 | Exercise / conversion · M | +4,000 | $8.39 | +$33.6K | 8,290 |
| Barton Shane | Principal Accounting Officer | Jun 30 | Exercise / conversion · M | +4,290 | $10.85 | +$46.5K | 4,290 |
| Barton Shane | Principal Accounting Officer | Jun 29 | Open-market sale · S | −42,350 | $25.21 | −$1.07M | 0 |
| Barton Shane | Principal Accounting Officer | Jun 29 | Exercise / conversion · M | +14,198 | $4.38 | +$62.2K | 42,350 |
| Barton Shane | Principal Accounting Officer | Jun 29 | Exercise / conversion · M | +8,958 | $4.30 | +$38.5K | 28,152 |
| Barton Shane | Principal Accounting Officer | Jun 29 | Exercise / conversion · M | +7,261 | $8.39 | +$60.9K | 19,194 |
| Barton Shane | Principal Accounting Officer | Jun 29 | Exercise / conversion · M | +9,301 | $10.85 | +$101K | 11,933 |
| Goldstein Dov A Md | Chief Financial Officer | Apr 23 | Exercise / conversion · M | +3,542 | $4.38 | +$15.5K | 36,575 |
| Rubin Paul D | Chief Medical Officer | Apr 01 | Open-market sale · S | −8,820 | $17.81 | −$157K | 0 |
| Rubin Paul D | Chief Medical Officer | Apr 01 | Exercise / conversion · M | +3,383 | $6.57 | +$22.2K | 8,820 |
| Rubin Paul D | Chief Medical Officer | Apr 01 | Exercise / conversion · M | +5,437 | $4.11 | +$22.3K | 5,437 |
| Rubin Paul D | Chief Medical Officer | Mar 02 | Open-market sale · S | −7,433 | $20.30 | −$151K | 0 |
| Rubin Paul D | Chief Medical Officer | Mar 02 | Exercise / conversion · M | +2,000 | $6.57 | +$13.1K | 7,433 |
| Rubin Paul D | Chief Medical Officer | Mar 02 | Exercise / conversion · M | +5,433 | $4.11 | +$22.3K | 5,433 |
| Goldstein Dov A Md | Chief Financial Officer | Mar 01 | Exercise / conversion · M | +3,542 | $4.38 | +$15.5K | 33,033 |
| Rubin Paul D | Chief Medical Officer | Feb 02 | Open-market sale · S | −7,433 | $18.75 | −$139K | 0 |
| Rubin Paul D | Chief Medical Officer | Feb 02 | Exercise / conversion · M | +2,000 | $6.57 | +$13.1K | 7,433 |
Loading...